News Breaks |
|
|
| August 3, 2012 |
| 15:15 EDT |  | ENDP, TEVA, MYL | FDA approves first generic versions of Singulair to treat asthma, allergies
The FDA approved the first generic versions of Singulair, or montelukast sodium, for use in adults and children to control asthma symptoms and to help relieve symptoms of indoor and outdoor allergies. Apotex, Aurobindo Pharma, Endo Pharmaceuticals (ENDP), Glenmark Generics, Kudco Ireland, Mylan (MYL), Roxane Laboratories, Sandoz, Teva Pharmaceuticals (TEVA), and Torrent Pharmaceuticals have gained FDA approval for generic montelukast tablets. Apotex, Aurobindo, Endo, Kudco, Mylan, Roxane, Sandoz, Teva, and Torrent have received approval for chewable tablets. Teva has received approval for the oral granule form. |
|
|
News For ENDP;MYL;TEVA From The Last 14 Days Check below for free stories on ENDP;MYL;TEVA the last two weeks. |
|
|
| May 22, 2013 |
| 16:23 EDT | | TEVA | Alexza Pharmaceuticals chief commercial officer to leave company
 Subscribe for More Information |
|
| 11:53 EDT |  | MYL | High option volume stocks: UAN MYL ALNY SKS XIDE
Subscribe for More Information |
|
| May 21, 2013 |
| 07:35 EDT | | MYL | Mylan: Appellate Court rules in favor of company in patent infringement case
Subscribe for More Information |
|
| May 20, 2013 |
| 11:27 EDT | | TEVA, MYL | Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva
Subscribe for More Information |
|
| May 17, 2013 |
| 14:48 EDT |  | MYL | Actavis may bid for Warner Chilcott to ward off takeover, Reuters says
Subscribe for More Information |
|
| 13:56 EDT | | MYL | Actavis may purchase Warner Chilcott as takeover defense, Reuters reports
Over past few weeks, Actavis (ACT) has "spurned approaches" from Valeant (VRX) and Mylan (MYL), and has instead pursued a bid for Warner Chilcott (WCRX), according to Reuters, citing people familiar with the situation. |
|
| 11:53 EDT | | ENDP | Options with decreasing implied volatility: SGMO ARNA CSC ENDP
Subscribe for More Information |
|
| 07:31 EDT | | MYL | Mylan launches generic Tricor tablets
Subscribe for More Information |
|
| May 16, 2013 |
| 10:03 EDT |  | ENDP | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 08:27 EDT | | ENDP | Endo Health upgraded to Buy from Neutral at Buckingham
Buckingham upgraded Endo Health based on attractive risk/reward and expectations for a more detailed strategy from the new CEO, maybe by Q2 results. Price target remains $41. |
| |
| May 15, 2013 |
| 19:37 EDT | | MYL | Novartis weighing Actavis bid, WSJ reports
Subscribe for More Information |
|
| 17:36 EDT | | MYL | Paulson gives quarterly update on stakes
Subscribe for More Information |
|
| 11:42 EDT | | MYL | Mylan launches generic Zomig tablets
Subscribe for More Information |
|
| 07:03 EDT |  | MYL | Mylan highly unlikely to acquire Actavis, says Barclays
Subscribe for More Information |
|
| May 14, 2013 |
| 13:55 EDT | | MYL | Actavis weighing over $5B bid for Warner Chilcott, snubbed Mylan, Bloomberg says
Subscribe for More Information |
|
| 13:22 EDT | | MYL | Actavis turned down $15B takeover bid from Mylan, Bloomberg reports
Subscribe for More Information |
|
| May 13, 2013 |
| 09:44 EDT | | TEVA | Several companies reportedly interested in buying Adcock Ingram, Globes says
Subscribe for More Information |
|
| 09:27 EDT |  | ENDP | Endo Health downgraded to Market Perform from Outperform at William Blair
|
|
| 09:25 EDT | | ENDP | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 09:04 EDT |  | ENDP | Endo Health falls 4.8%
Endo Health is down 4.8%, or $1.67, to $33.30 |
| |
|
|
|
|
